Studies have shown that STMN1 is highly expressed in various cancers, including gastric, ovarian, and prostate cancers [18–20], and its increased expression was associated with resistance of tumor cells to the anti-tumor effects of microtubule inhibitors. Here, STMN1 is linked to prostate carcinoma.